Related references
Note: Only part of the references are listed.Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue
Ignace C. Roseboom et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2022)
Development and validation of a high-performance liquid chromatography tandem mass spectrometry method for the quantification of the antiparasitic and antifungal drug amphotericin B in human skin tissue
Ignace C. Roseboom et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2022)
Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis
Rakhi Kusumesh et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2021)
Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
Luka Verrest et al.
CLINICAL INFECTIOUS DISEASES (2021)
Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis
V Ramesh et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma
Ignace C. Roseboom et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2020)
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India
Vishal Goyal et al.
PLOS NEGLECTED TROPICAL DISEASES (2020)
The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis
Joyce Pijpers et al.
PLOS NEGLECTED TROPICAL DISEASES (2019)
Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies
Dinesh Mondal et al.
CLINICAL INFECTIOUS DISEASES (2019)
Safety and Effectiveness of Short-Course AmBisome in the Treatment of Post-Kala-Azar Dermal Leishmaniasis: A Prospective Cohort Study in Bangladesh
Margriet den Boer et al.
CLINICAL INFECTIOUS DISEASES (2018)
Development and Evaluation of a Novel Loop-Mediated Isothermal Amplification Assay for Diagnosis of Cutaneous and Visceral Leishmaniasis
Emily Rebecca Adams et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment
Shomik Maruf et al.
PLOS NEGLECTED TROPICAL DISEASES (2018)
The immunology of post-kala-azar dermal leishmaniasis (PKDL)
Eduard E. Zijlstra
PARASITES & VECTORS (2016)
Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol
D. Mondal et al.
BMJ OPEN (2016)
Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India
V. Ramesh et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh-A Case Report
Ulrika Marking et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Thomas P. C. Dorlo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
Ahmed Musa et al.
PLOS NEGLECTED TROPICAL DISEASES (2012)
Who Is a Typical Patient with Visceral Leishmaniasis? Characterizing the Demographic and Nutritional Profile of Patients in Brazil, East Africa, and South Asia
Michael O. Harhay et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2011)
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial
Shyam Sundar et al.
LANCET (2011)
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients
Thomas P. C. Dorlo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Immunochemotherapy of persistent post-kata-azar dermal leishmaniasis: a novel approach to treatment
Ahmed Mudawi Musa et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2008)
Efficacy of liposomal amphotericin B (AmBisome®) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)
AM Musa et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2005)
Post-kala-azar dermal leishmaniasis
EE Zijistra et al.
LANCET INFECTIOUS DISEASES (2003)
The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features
AM Musa et al.
ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY (2002)
Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis
EE Zijlstra et al.
BRITISH JOURNAL OF DERMATOLOGY (2000)
Share Paper
